Beijing Konruns Pharmaceutical Co Ltd - Asset Resilience Ratio
Beijing Konruns Pharmaceutical Co Ltd (603590) has an Asset Resilience Ratio of 10.55% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 603590 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Beijing Konruns Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 603590 current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down Beijing Konruns Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 603590 total debt and obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥430.11 Million | 10.55% |
| Total Liquid Assets | CN¥430.11 Million | 10.55% |
Asset Resilience Insights
- Moderate Liquidity: Beijing Konruns Pharmaceutical Co Ltd has 10.55% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Beijing Konruns Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Beijing Konruns Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
Annual Asset Resilience Ratio for Beijing Konruns Pharmaceutical Co Ltd (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Beijing Konruns Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.22% | CN¥500.43 Million ≈ $73.23 Million |
CN¥4.09 Billion ≈ $599.23 Million |
+0.72pp |
| 2024-12-31 | 11.50% | CN¥450.66 Million ≈ $65.95 Million |
CN¥3.92 Billion ≈ $573.57 Million |
+1.01pp |
| 2023-12-31 | 10.48% | CN¥396.41 Million ≈ $58.01 Million |
CN¥3.78 Billion ≈ $553.25 Million |
+2.30pp |
| 2022-12-31 | 8.19% | CN¥280.37 Million ≈ $41.03 Million |
CN¥3.42 Billion ≈ $501.16 Million |
+7.92pp |
| 2021-12-31 | 0.27% | CN¥9.04 Million ≈ $1.32 Million |
CN¥3.37 Billion ≈ $493.33 Million |
-4.52pp |
| 2020-12-31 | 4.79% | CN¥181.36 Million ≈ $26.54 Million |
CN¥3.79 Billion ≈ $553.96 Million |
+4.73pp |
| 2019-12-31 | 0.06% | CN¥2.00 Million ≈ $293.16K |
CN¥3.17 Billion ≈ $464.43 Million |
-- |
About Beijing Konruns Pharmaceutical Co Ltd
Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations. It is also involved in the development of drug candidates, including ZY5301 that is in p… Read more